AGP Executive Report
Last update: 3 hours agoUS Pharma Tariffs, but With a Twist: The U.S. Commerce Department says “specialty pharmaceutical” products (including orphan drugs, nuclear medicines, plasma therapies, fertility drugs, cell/gene therapies, and antibody-drug conjugates) can qualify for a 0% tariff under Section 232—but eligibility isn’t automatic and depends on product-level details and qualifying trade/security frameworks. Liechtenstein in the Mix: Liechtenstein is listed among eligible jurisdictions for the zero-tariff treatment, alongside Switzerland and the EU, as the wider 100% tariff expansion hits mid-sized and smaller drugmakers from Sept. 29. EFTA-India Trade Check-In: India and EFTA (including Liechtenstein) will review the TEPA deal at an October summit, aiming to unblock market access and investment after export declines. Rare Disease Breakthrough in Europe: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone) for childhood cerebral adrenoleukodystrophy (cALD), with a first launch expected in Germany. Digital Identity Milestone: A look back at how .eu became everyday European internet infrastructure—relevant for Liechtenstein’s online presence. Healthcare Staffing Rule Shift: Ireland plans a temporary relaxation of the “50:50 rule” for non-EEA workers to ease healthcare staffing shortages.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report ]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/24259881-872312346-b2defa6b4904a34b5dfa8d86ebaaae1c7a81931b-1280x720-100x56.png)
